InvestorsHub Logo
icon url

pennstreet

04/01/13 10:53 PM

#39751 RE: Crow3 #39749

Crow3

It is most obvious to Cdex shareholders that it is a mind blower that Cdex is still open for business, and will be getting $200,000 in the next couple of weeks from Kuwait. Cdex will also begin getting additional revenue from the 10 CCT's as well.

Cdex will be increasing their revenue stream from this sell. Cdex is doing exactly what they should be, adding income to the bottom line.

Now that the crew has delivered the 10 CCT's, their attention will be focused on the G4's and the delivery of them in this second quarter.

The ValiMed Medication Validation and Narcotics Return System (Model CCT), is a lightweight,
compact table top instrument that can be used in virtually any clinical environment where high-risk IV
medications are compounded before being dispensed to the patient, or where narcotics are returned
after being dispensed. CDEX’s ValiMed drug validation technology helps healthcare providers ensure
patient safety and control costs by reducing medication errors and mitigating drug diversion.

Gotta love the word "compounded", "high-risk IV medications", "ensure patient safety" , "control cost", "reducing medication errors", and "mitigating drug diversion".

One might expect this type of technology takes very intense specialization, to say the least.